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Introduction
Colorectal cancer (CRC) is the third most common cancer and the fourth-leading cause of cancer-related deaths worldwide (Favoriti et al., 2016) . The cornerstones of CRC therapy are surgery, neoadjuvant radiotherapy and adjuvant chemotherapy. For patients with irresectable distant metastases, chemotherapy is the primary choice of treatment (Brenner et al., 2014) .
Epigenetic alterations are known to play a key role in CRC development (Okugawa et al., 2015) . Epigenetics is the study of heritable alterations in gene expression that are not mediated by changes in DNA sequence, including DNA methylation, histone modification, nucleosome remodelling and non-coding RNA expression (Bird, 2002; Liu et al., 2016) . Histone modifications include acetylation, methylation, phosphorylation, ubiquitylation, ADPribosylation and deamination (Minucci and Pelicci, 2006) . Histone acetyltransferases (HATs) and deacetylases (HDACs) are key enzymes involved in maintaining the levels of histone acetylation. Histone acetylation is an indicator of active transcription. Therefore, HATs and HDACs are associated with active and inactive genes respectively (Wang et al., 2009) . Hyperacetylation of histones relaxes the chromatin structure and increases transcriptional activity, whereas hypoacetylation of histones condenses the chromatin structure (Codd et al., 2009) . Trichostatin A (TSA) is an HDAC inhibitor, which increases the level of histone acetylation and up-regulates transcription (Codd et al., 2009) .
The concentrative nucleoside transporter 2 (SLC28A2, CNT2) is a sodium-dependent transporter, present in many tissues, including the kidney, liver, heart, brain, placenta, pancreas, skeletal muscle, colon, rectum, duodenum, jejunum and ileum (Wang et al., 1997; Pennycooke et al., 2001) . CNT2 mediates the uptake of both natural nucleosides and nucleoside-derived drugs, including cladribine (2-CdA), fludarabine and ribavirin, which are used widely for the treatment of cancer and viral infections (Mackey et al., 1998; Baldwin et al., 1999; Gray et al., 2004; Owen et al., 2006; Minuesa et al., 2008; Elwi et al., 2009) . However, in tumour tissue samples from the kidney, stomach, rectum and small intestine, CNT2 expression is reduced, leading to resistance to nucleoside drugs (Pennycooke et al., 2001; Lotfi et al., 2003) . It has recently been reported that CNT2 is also associated with cell differentiation and energy metabolism in cells (Pastor-Anglada et al., 2007; Huber-Ruano et al., 2010) . Despite the clinical importance of CNT2, the regulation of its expression in cancer has not yet been elucidated. In this study, we found that CNT2 expression was significantly repressed in tumour tissue samples from patients with CRC and we have determined the epigenetic mechanisms underlying this finding. We also used cell lines derived from CRC, HCT15 and HT29, to assess the effects of HDAC inhibition on CNT2 expression and on cellular uptake of 2-CdA. We also tested the effects of a combination of HDAC inhibitors and 2-CdA in HCT15 and HT29 cells. This combination enhanced the anti-cancer effects of 2-CdA and led to the reversal of CNT2 repression.
Methods
Tumour tissue samples from 44 patients with CRC were drawn from the Specimen Bank of Zhejiang Cancer Hospital at Hangzhou, China, with the approval by the Institutional Review Board of Zhejiang Cancer Hospital. Patient information is provided in Supporting Information Table S1 .
RNA extraction and RT-qPCR analysis
Total RNA from tissues and cells was isolated using different commercial kits and then reverse transcribed to cDNA with PrimeScript RT Master Mix, following the manufacturer's instructions. Quantitative real-time PCR was performed with SYBR Premix EX Taq using specific primers listed in Supporting Information Table S2 . qPCR assays were performed in 96-well optical reaction plates, using the Applied Biosystem Step-One Plus (Applied Biosystems, Waltham, USA). qPCR assays were conducted in duplicate wells for each sample. For all experiments, the following qPCR conditions were use: denaturation at 95°C for 30 s, followed by 40 cycles at 95°C for 5 s and then at 60°C for 30 s. The relative expression of transcripts was quantified by normalization to GAPDH in cell lines and PPIB in patient tissues as GAPDH was more stable in cell lines and PPIB was more stable in tissues. 2
À△Ct method was used to calculate gene expression in tissues, 2 À△△Ct was used to calculate gene expression in cell lines (Schmittgen and Livak, 2008) .
Western blot
Tissues were lysed with RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, sodium orthovanadate, sodium fluoride, EDTA, leupeptin; Beyotime, Shanghai, China). The supernatant was separated by centrifugation (14560 x g for 10 min. at 4°C). Protein concentration was determined by BCA protein assay kit (Beyotime). Protein lysates were heated at 100°C for 10 min with loading buffer. Proteins were isolated under following conditions: 90 V, 30 min in 5% stacking gel and then 120 V, 2 h in 10% separating gel. After that, proteins were transferred to PVDF membranes (Millipore, MA). The membranes were blocked using 5% BSA at room temperature for 3 h and then incubated with anti-SLC28A2 and anti-GAPDH respectively. The immune complexes were visualized with EZ-ECL (BI, USA) according to the manufacturer's protocol. 
Cell cultures and drug treatment

Bisulfite sequencing analysis
This part of experiment was outsourced to Sangon Biotech (Shanghai, China). Genomic DNA from tissues was isolated with QIAamp DNA Mini Kit (Qiagen, Leipzig, Germany) and quantified using NanoDrop 2000. Then, 2 μg DNA was treated with sodium bisulfite for 16 h at 50°C, paroline was added to avoid oxidation as well as evaporation of water. After that, DNA was collected with a UNIQ column. Bisulfite sequencing PCR primers were designed by Sangon Biotech (…China) and listed in Supporting Information Table S2 . PCR products were extracted using SanPrep Column PCR Product Purification Kit (Sangon Biotech) according to the manufacturer's instructions. The purified PCR products were cloned into pUC18-T vector and then transformed into competent cells. The plasmid was extracted with SanPrep Column Endotoxin-Free Plasmid Mini-Preps Kit (Sangon Biotech), followed by sequencing. For patients #42, #43 and #44, five clones were sequenced, for patients #15, #18 and #28, 10 clones were sequenced. SeqMan was used to analyse the data.
Uptake experiments
HCT15 cells were seeded at 1 × 10 5 cells cm À2 in 24-well plates, HT29 cells were seeded at 7 × 10 4 cells cm À2 in 24-well plates. They were separated into two groups, experimental group was treated with medium containing 1 μΜ TSA or 1 μΜ FK228 for 24 h, reference group was treated with 0.1% DMSO. After 24 h treatment, cells were washed with upB solution (composition in mM: NaCl, 125; KCl, 4.83; MgSO 4 , 1.27; KH 2 PO 4 , 1.18; CaCl 2 , 1.17; HEPES, 25.2; pH 7.2-7.4). For the uptake of ribavirin, cells were incubated with upB solution containing 25 μΜ ribavirin for 2 min at 37°C; for the uptake of 2-CdA, cells were incubated with upB solution containing 40 μΜ 2-CdA for 30 min at 37°C. Incubation, in both cases, was followed by washing cells with cold PBS, three times immediately. Finally, the cell lysates were collected using 0.1% SDS, the concentration of proteins was detected by BCA protein assay kit, the concentration of ribavirin and 2-CdA was measured by LC-MS/MS.
Chromatin immunoprecipitation (ChIP)
Tissues and cells were cross-linked using formaldehyde (Thermo Forma, Waltham, USA) at a final concentration of 1.1%, tissues were incubated for 30 min at room temperature, the incubation time for cells were 15 min. Then, the crosslinking was quenched with 0.125 M glycine. To shear the chromatin, tissues were treated with 10 U MNase mL
À1
(Thermo Scientific (Waltham, USA ) for 10 min at 37°C, followed by sonication for 30 min at 4°C; for cells, the sonication time was 15 min. Sheared chromatin was incubated with 1.5 μg antibody at 4°C overnight, then the mixture was incubated with Protein G beads (Millipore) for 4-6 h at 4°C. Finally, the beads were washed and DNA was collected for subsequent RT-qPCR (Lee et al., 2006) . Primers used in ChIP-qPCR were listed in Supporting Information Table S2 . The enrichment was indicated as % of input. 
Cell viability assay and drug combination analysis
HCT15 cells were seeded at 5.5 × 10 4 cells cm À2 and HT29
cells were seeded at 8 × 10 4 cells cm À2 in 96-well plates, and both were cultured for 24 h before drug treatment. According to the treatment, cells were divided into three groups: combination group, cells were treated with different concentrations of TSA for 24 h followed by various concentrations of 2-CdA in the absence of TSA for 24 h; TSA group, 2-CdA treatment in the later 24 h was replaced with DMSO; 2-CdA group, TSA treatment in the first 24 h was replaced with DMSO. The dosing schedule was same for combinations of FK228 and 2-CdA. Cell viability was evaluated by 1-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl-formazan (MTT) assay. The medium was discarded and cells were washed twice with PBS. Then, 180 μL serum-free medium and 20 μL 5 mg·mL
À1
MTT was added to cells and incubated at 37°C for 4 h in dark. And then, the supernatant was replaced by 200 μL of DMSO, cells were agitated at 37°C for 10 min, the absorbance were detected at 570 and 630 nm. The assay was performed in quadruplicate for each drug concentration.
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2018) . Results were expressed as mean ± SEM. The Student's t-test was used for the statistical comparison when there were two experimental groups, ANOVA was used when more than two experimental groups were compared. P < 0.05 was accepted as showing statistical significance.
Materials
The kit used to extract total RNA from tissue was RNA mini-prep kit (Tiangen, Beijing, China). The kit used to extract total RNA from cell bought from Axygen (Tewkesbury, USA), PrimeScript RT Master Mix (Takara, Japan); SYBR Premix EX Taq (Takara, Japan 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS Guide to PHARMACOLOGY (Harding et al., 2018) , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 (Alexander et al., 2017a,b) .
Results
CNT2 is repressed in CRC
Data from Oncomine™ (Compendia Bioscience, Arm Arbor, MI) demonstrated that CNT2 mRNA expression was markedly repressed in CRC tumour tissues (Supporting Information Figure S1 ). To confirm this result, we analysed CNT2 expression in our CRC samples, using RT-qPCR. We found that CNT2 mRNA expression was significantly repressed in CRC tumour tissues compared with that in adjacent normal tissues. Our data were consistent with the data from Oncomine ( Figure 1A ). Some other transporters of interest were also detected with the RT-qPCR, but their expression levels were not significantly changed in CRC tumour tissues (Supporting Information Figure S2) . Results of the Western blot experiments also confirmed this difference between tumour and normal tissues ( Figure 1B ). Taken together, these results demonstrated that CNT2 expression was repressed at both mRNA and protein levels in CRC, regardless of gender, age, location, TNM stage and cancer subtype (Supporting Information Figure S3 ).
Histone hypoacetylation represses CNT2 in CRC
Next, we attempted to identify the mechanism underlying CNT2 repression in CRC. Because epigenetics plays key roles in gene expression regulation, we evaluated DNA methylation and histone acetylation levels in the promoter region of CNT2 in CRC samples. Interestingly, we found that H3K9Ac, H3K18Ac and H4Ac levels were decreased in CRC tissues compared with adjacent normal tissues ( Figure 2A ). H3K9Ac, H3K18Ac and H4Ac are associated with active transcriptional states (Kimura, 2013; Okugawa et al., 2015) . However, we failed to detect aberrant DNA methylation in CRC tissues (Supporting Information Figure S4 ). We also treated cells with DAC, a demethylating reagent that blocks cellular DNA methyltransferases and found the CNT2 expression was not elevated. Moreover, methylation analysis of CNT2 promoter region did not show significant difference between CRC tumour tissues and adjacent normal controls. We therefore concluded that DNA methylation was not the main cause of CNT2 repression in CRC.
In CRC cell lines we also found that histone hypoacetylation contributed to CNT2 repression. We treated HCT15 and HT29 cells with TSA and found that CNT2 transcription was activated in both cell lines in a dosedependent manner ( Figure 2B ). Ribavirin, a known substrate of CNT2 (Mori et al., 2010) , was used to determine whether the transport function of CNT2 was also up-regulated. As shown in Figure 2C , up-regulation of CNT2 by TSA did lead to functional changes. After treatment with TSA, we used ChIP-qPCR to detect changes in histone acetylation state in the CRC cell lines. We found that the acetylation at H3K9Ac, H3K18Ac and H4Ac increased after TSA treatment ( Figure 2D ). For all the ChIP-qPCR analyses mentioned above, we designed three pairs of primers to cover 2000 bp of the promoter region. These primer pairs showed similars patterns of histone modification, which indicated that all parts of the promoter region were likely to be acetylated. The RT-qPCR results for the other two pairs of primers are shown in Supporting Information Figure S5 . Taking these results together, we concluded that histone hypoacetylation repressed CNT2 in CRC.
Figure 1
CNT2 is repressed in CRC. (A) RT-qPCR analysis of CNT2 transcription in matched CRC tissues and adjacent normal tissues normalized to reference gene PPIB . Individual data points are shown, with means and SEM indicated by horizontal lines; n = 44, *P < 0.05, significantly different as indicated; two-tailed paired t-test. (B) Western blot of CNT2 and GAPDH in matched CRC tissues (24C, 23C) and adjacent normal tissues from the same individual (23N, 24N) . Normal liver tissue was used as the positive control (PC), as recommended.
Up-regulation of HDAC7 in CRC results in CNT2 repression
TSA inhibits Zn (II)-dependent class I and class II histone deacetylases, including HDAC1-10 (Codd et al., 2009; Seto and Yoshida, 2014) . Therefore, we investigated which HDAC was the main factor responsible for CNT2 repression in CRC. Among all the HDACs mentioned above, HDAC7 was the only one up-regulated in CRC tissues compared with adjacent normal tissues ( Figure 3A , Supporting Information Figure S6 ), which indicated that HDAC7 may be the enzyme responsible for CNT2 repression. This possibility was confirmed in the CRC cell lines. In HCT15 and HT29 cells, HDAC7 mRNA level was markedly decreased after treatment with TSA for 24 h ( Figure 3B ). We then designed two siRNAs for HDAC7. After transient transfection with the siRNA, we found that HDAC7 mRNA level was decreased in HCT15 and HT29 cell lines, whereas CNT2 expression was up-regulated. We also designed siRNAs for other HDACs and, although the expression of the corresponding HDACs decreased after transfection with the relevant siRNAs, CNT2 expression was not elevated (Supporting Information Figures S7 and S8 ). These experiments showed that HDAC7 expression was up-regulated in CRC, which resulted in hypoacetylation at the CNT2 promoter region and subsequent repression of CNT2 in CRC.
CNT2 activation by HDAC inhibitors sensitizes CRC cell lines to the anti-cancer drug 2-CdA
2-CdA, a substrate of CNT2, is a drug used to treat hairy cell leukaemia, B-cell chronic lymphocytic leukaemia; and its application in multiple sclerosis is recently being investigated (Juliusson and Samuelsson, 2011; Comi et al., 2013) . FK228 is a selective inhibitor of class I and II HDAC enzymes and is approved for the treatment of T-cell lymphoma (VanderMolen et al., 2011) . On the basis of the central role of histone hypoacetylation in CNT2 repression in CRC, we examined whether epigenetic activation of CNT2 by HDAC inhibitors could sensitize CRC cells to 2-CdA. As shown in Figure 4A and B, pretreatment with TSA and FK228 markedly decreased the IC 50 of 2-CdA in HCT15 and HT29 cells, indicating that the anti-cancer effect of 2-CdA was increased. The IC 50 of TSA and 2-CdA combined was 12.95 and 13.73 μΜ in HCT15 and HT29 CRC cell lines respectively. However, when 2-CdA alone was used, the IC 50 was 40.38 μΜ in HCT15 and 35.31 μΜ in HT29. The combination of FK228 and 2-CdA also gave similar results. To further determine whether the decrease of IC 50 was due to enhanced uptake of 2-CdA, we evaluated cellular accumulation of 2-CdA in HCT15 and HT29 cell lines. After TSA or FK228 treatment, the uptake of 2-CdA was increased ( Figure 4C, D) . On the basis of these results, we concluded that CNT2 up-regulation, resulting from TSA pretreatment, can enhance the anti-cancer effect of 2-CdA in CRC cell lines.
Discussion
The transporter CNT2 is physiologically important because it plays critical roles in nucleoside homeostasis at the cellular level by mediating influx of extracellular nucleosides into cells (Gray et al., 2004) . Activity of CNT2 is also pharmacologically important because it mediates the transport of many clinically relevant drugs. In addition, association between CNT2 and energy metabolism has also been confirmed as CNT2 mediates high-affinity uptake of adenosine, an important molecule that stimulates glycogenolysis and gluconeogenesis through its interaction with A 2B receptors (Yasuda et al., 2003; Duflot et al., 2004; Huber-Ruano et al., 2010) . Despite all these important functions of CNT2, regulation of CNT2 expression has not been thoroughly elucidated.
To our knowledge, this is the first study of CNT2 repression in CRC using epigenetics. First, we analysed data from the Oncomine Cancer Transcriptome database and found that CNT2 was transcriptionally repressed in most CRC. This result was also confirmed at mRNA level using RT-qPCR and at protein level using Western blots. Second, we tried to reveal the mechanism underlying this repression, following the example of Okugawa et al. (2015) . Both DNA methylation and histone acetylation levels of the CNT2 promoter region were evaluated. The histone acetylation level was reduced, especially at sites H3K9Ac, H3K18Ac and H4Ac. In contrast, DNA methylation did not show any significant change. These results were shown with experiments involving both CRC tissues and CRC cell lines. Therefore, we concluded that histone hypoacetylation was the main cause of CNT2 repression in CRC, and that this repression could be reversed with TSA treatment. In addition, with siRNA knockdown and RT-qPCR, we found that HDAC7 was the key enzyme responsible for hypoacetylation.
This mechanism may also be clinically important because combining TSA or FK228 with 2-CdA enhanced the anticancer actions of 2-CdA. Resistance to 2-CdA has become a major challenge for its effectiveness and decreased nucleoside transport is one of the main reasons (Lotfi et al., 2003) . However, in our experiments, when 2-CdA was combined with TSA, the cellular uptake of the nucleoside was increased. Moreover, as CNT2 is associated with energy metabolism, the mechanism identified in this study may also be helpful in explaining development of CRC, but this hypothesis needs further investigation.
In summary, our study showed that expression of HDAC7 was increased in CRC, and this leads to histone hypoacetylation at the CNT2 promoter region, especially at sites H3K9Ac, H3K18Ac and H4Ac. Such hypoacetylation condenses the chromatin structure and down-regulates CNT2 expression. On treatment with TSA, an inhibitor of HDAC, all these effects were reversed. The findings of this study can be applied to investigations of multi-drug resistance, because reduced CNT2 expression correlated with decreased nucleoside drug uptake, as shown in our drug combination experiment.
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Additional supporting information may be found online in the Supporting Information section at the end of the article.
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